Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Verapamil on HRS-1893 Pharmacokinetics in Healthy Subjects
NCT06354556Phase 1Completed
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Apr 2024
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HRS-1893 in hypertrophic cardiomyopathy (HCM), sponsored by Shandong Suncadia Medicine Co., Ltd. Primary endpoints: Maximum observed serum concentration, Area under the plasma concentration versus time curve from time zero to last measurable timepoint and 1 more. Started Apr 2024; status: completed.
02
Drugs
HRS-1893
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT06354556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06354556.